Evidence map›Paper›PMID 32496628›Full record

ArticleClinical pharmacology and therapeutics2020

Exome Sequencing Reveals Common and Rare Variants in F5 Associated With ACE Inhibitor and Angiotensin Receptor Blocker-Induced Angioedema.

Cyrielle Maroteau, Moneeza Kalhan Siddiqui, Abirami Veluchamy, Fiona Carr, Myra White, Andrew J Cassidy, Ekaterina V Baranova, Eva R Rasmussen, Niclas Eriksson, Katarzyna M Bloch and 13 more

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Common Statin Intolerance Variants inFrontiers in genetics · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 9 institutions in 5 countries.

Cyrielle MaroteauDivision of Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.ORCID 0000-0001-7816-5508
Moneeza Kalhan SiddiquiDivision of Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
Abirami VeluchamyDivision of Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
Fiona CarrDivision of Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
Myra WhiteDivision of Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
Andrew J CassidyTayside Centre for Genomic Analysis, School of Medicine, University of Dundee, Dundee, UK.
Ekaterina V BaranovaDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.
Eva R RasmussenDepartment of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Denmark.
Niclas ErikssonDepartment of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-2152-4343
Katarzyna M BlochDepartment of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Nancy J BrownDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Anette BygumOPEN Patient data Explorative Network, Odense University Hospital, Odense, Denmark.
Par HallbergDepartment of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID 0000-0003-3465-3280
Malgorzata KarawajczykDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
Patrik K E MagnussonSwedish Twin Registry, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Qun-Ying YueUppsala Monitoring Centre, WHO Collaborating Centre, Uppsala, Sweden.
Ann-Christine SyvänenDepartment of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Christian von BuchwaldDepartment of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Denmark.
Ana AlfirevicDepartment of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Anke H Maitland-van der ZeeDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.
Mia WadeliusDepartment of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-6368-2622
Colin N A PalmerDivision of Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
PREDICTION-ADR
University of Dundee · GBUppsala University · SEUniversity of Copenhagen · DKUniversity of Liverpool · GBUtrecht University · NLKarolinska Institutet · SEOdense University Hospital · DKUppsala Monitoring Centre · SEVanderbilt University Medical Center · US

Funding

Pharmacogenetics of ACE inhibitor-associated angioedema R01HL079184 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BROWN, NANCY J. · 2005 to 2014
$3.2M
Medical Research Council G0601261Medical Research Council MC_QA137929NHLBI NIH HHS R01 HL079184Wellcome TrustWellcome Trust 099177/Z/12/Z
6 · The paper itself

Abstract

Angioedema occurring in the head and neck region is a rare and sometimes life-threatening adverse reaction to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). Few studies have investigated the association of common variants with this extreme reaction, but none have explored the combined influence of rare variants yet. Adjudicated cases of ACEI-induced angioedema (ACEI-AE) or ARB-induced angioedema (ARB-AE) and controls were recruited at five different centers. Sequencing of 1,066 samples (408 ACEI-AE, ARB-AE, and 658 controls) was performed using exome-enriched sequence data. A common variant of the F5 gene that causes an increase in blood clotting (rs6025, p.Arg506Gln, also called factor V Leiden), was significantly associated with both ACEI-AE and ARB-AE (odds ratio: 2.85, 95% confidence interval (CI), 1.89-4.25). A burden test analysis of five rare missense variants in F5 was also found to be associated with ACEI-AE or ARB-AE, P = 2.09 × 10

Indexed as

DNA Mutational AnalysisExome SequencingMutation, MissenseAgedAngioedemaAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCase-Control StudiesEuropeExomeFactor VFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMaleAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsFactor Vfactor V Leiden

Identifiers

PMID32496628
PMCPMC10306231
OpenAlexW3031020182

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.